PUBLISHER: The Business Research Company | PRODUCT CODE: 1764306
PUBLISHER: The Business Research Company | PRODUCT CODE: 1764306
Dysfunctional uterine bleeding (DUB) is characterized by abnormal uterine bleeding, typically caused by hormonal imbalances rather than structural issues. It primarily affects women of reproductive age and can manifest as heavy, prolonged, or irregular menstrual periods. DUB is diagnosed when no pelvic pathology, systemic illness, or pregnancy-related cause is identified. Treatment varies based on the severity and the patient's reproductive intentions.
The main categories of dysfunctional uterine bleeding are ovulatory and anovulatory. Ovulatory DUB occurs despite regular ovulation and often includes conditions like menorrhagia, polymenorrhagia, metrorrhagia, and dysmenorrhea. Diagnostic methods include hysteroscopy, ultrasonography, dilation and curettage, and endometrial biopsy. These techniques are used in managing menopause, dysfunctional uterine bleeding, endometrial cancer, contraception, hyperplastic precursor lesions, and other conditions. The primary end users include hospitals, clinics, diagnostic centers, and pharmaceutical companies.
The dysfunctional uterine bleeding market research report is one of a series of new reports from The Business Research Company that provides dysfunctional uterine bleeding market statistics, including the dysfunctional uterine bleeding industry global market size, regional shares, competitors with the dysfunctional uterine bleeding market share, detailed dysfunctional uterine bleeding market segments, market trends, and opportunities, and any further data you may need to thrive in the dysfunctional uterine bleeding industry. This dysfunctional uterine bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dysfunctional uterine bleeding market size has grown strongly in recent years. It will grow from $3.29 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be credited to the rising prevalence of hormonal imbalances, growing awareness of menstrual health, increased adoption of hormone therapy treatments, a higher number of women seeking gynecological care, and expanding research and development in women's health.
The dysfunctional uterine bleeding market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth projected for the forecast period is driven by the increasing prevalence of menstrual disorders, heightened awareness of women's health, greater adoption of advanced diagnostic techniques, expanding healthcare infrastructure, and a growing demand for minimally invasive treatments. Key trends during this period include progress in non-hormonal treatment options, improvements in diagnostic tools for menstrual disorders, development of minimally invasive surgical methods, innovations in menstrual health tracking technologies, and enhanced patient awareness and education initiatives.
The rising prevalence of menstrual disorders is expected to drive the growth of the dysfunctional uterine bleeding market in the coming years. Menstrual disorders encompass any irregularities or abnormalities in the menstrual cycle, such as changes in the frequency, duration, or volume of bleeding. This increase in menstrual disorders is fueled by greater awareness, lifestyle changes, and improved diagnostic methods that allow more cases to be identified and treated. Dysfunctional uterine bleeding aids in understanding menstrual disorders by detecting abnormal uterine bleeding patterns that are not linked to structural or systemic diseases, thereby supporting accurate diagnosis and treatment. For example, in December 2023, the Trust for London, a UK-based nonprofit, reported that 2.8 million people in the UK struggled to afford period products-equivalent to one in five menstruating individuals-and a significant rise from 12% in 2022 to 21% in 2023. Thus, the growing prevalence of menstrual disorders is contributing to the expansion of the dysfunctional uterine bleeding market.
Leading companies in the dysfunctional uterine bleeding market are concentrating on developing new treatments, such as oral GnRH antagonists, to offer effective, non-surgical options that reduce heavy menstrual bleeding by regulating hormone levels. An oral GnRH antagonist works by blocking gonadotropin-releasing hormone receptors, lowering estrogen levels, and shrinking uterine fibroids without the need for invasive procedures. For example, in September 2024, Theramex, a UK-based pharmaceutical firm, launched Yselty (linzagolix), an oral, once-daily GnRH antagonist aimed at treating heavy menstrual bleeding associated with uterine fibroids. This medication offers flexible dosing to better customize treatment for individual patients. It effectively alleviates symptoms while preserving patients' quality of life and supports fertility preservation during treatment. Overall, Yselty represents an innovative strategy for managing bleeding related to uterine fibroids.
In January 2025, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition adds the Sonata System to Hologic's portfolio-an innovative, incision-free treatment for uterine fibroids linked to heavy menstrual bleeding. The technology offers uterus-preserving options, strengthening Hologic's position in the abnormal uterine bleeding market. Gynesonics Inc., also based in the US, specializes in non-surgical medical devices that treat conditions causing dysfunctional uterine bleeding (DUB).
Major players in the dysfunctional uterine bleeding market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Medtronic plc, Boston Scientific Corporation, Smith & Nephew plc, Sun Pharmaceutical Industries Ltd., Hologic Inc., Sumitomo Pharma, Karl Storz SE & Co. KG, Cook Medical Incorporated, Gedeon Richter Plc, Lupin Ltd., Torrent Pharmaceuticals Ltd., CooperSurgical Inc., Ferring Pharmaceuticals SA, Minerva Surgical Inc., and Medgyn Products Inc.
North America was the largest region in the dysfunctional uterine bleeding market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysfunctional uterine bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dysfunctional uterine bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dysfunctional uterine bleeding market includes revenues earned by entities by providing services such as emergency care services, fertility and reproductive health services, and telemedicine and virtual care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dysfunctional Uterine Bleeding Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dysfunctional uterine bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for dysfunctional uterine bleeding ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysfunctional uterine bleeding market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.